A maker of titanium and bone implants for the sacroiliac (SI) joint, where the spine meets the pelvis. Its iFuse line of triangular, 3D-printed titanium implants is used in minimally invasive surgery to fuse that joint and ease lower-back and pelvic pain. Founded in 2008 by orthopedic surgeon Dr. Mark Reiley, who also invented kyphoplasty, the company's name simply nods to its focus: "SI" stands for sacroiliac.
SI-BONE extends HQ lease one month to Aug 31, 2026 at $43,696/month
SI-BONE, Inc. and BIXBY SPE FINANCE 11, LLC entered into a Third Amendment to Lease on June 5, 2026.
Show detailsHide details
The amendment extends the lease for the 21,848 sq ft corporate headquarters at 471 El Camino Real, Santa Clara, CA for one month, from August 1, 2026 to August 31, 2026.
Base rent is $43,696 per month, with an option to extend one additional month to September 30, 2026 on the same terms.
At the June 4, 2026 Annual Meeting, shareholders elected directors Jeffrey W. Dunn and John G. Freund, M.D., ratified PricewaterhouseCoopers LLP as auditor, and approved executive compensation on an advisory basis.
The meeting had 38,905,031 shares present or represented by proxy, about 88% of outstanding shares.
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
SI-BONE reports record Q4 2025 revenue of $56.3M, up 15%, and positive adjusted EBITDA of $5.1M.
SI-BONE reported Q4 2025 worldwide revenue of $56.3 million, a 15.0% increase from $49.0 million in Q4 2024.
Show detailsHide details
Fiscal year 2025 worldwide revenue was $200.9 million, up 20.2% from $167.2 million in 2024.
The company achieved positive adjusted EBITDA of $5.1 million in Q4 2025 and $8.9 million for the full year 2025.
SI-BONE issued 2026 revenue guidance of $228.5 million to $232.5 million, implying growth of ~14% to ~16%.
Anshul Maheshwari was appointed Chief Operating Officer in addition to his role as Chief Financial Officer.
1.01 Entry into a Material Definitive Agreement · 2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
SI-BONE director Daniel Wolf resigns; consulting agreement accelerates RSU vesting
Daniel Wolf resigned from SI-BONE's Board of Directors on November 6, 2025, not due to any disagreement with the company.
Show detailsHide details
The Board reduced its size from nine to eight directors and appointed Thomas A. West to the Audit Committee.
SI-BONE entered a 12-month consulting agreement with Wolf for marketing, strategy, and business development support.
The consulting agreement accelerates vesting of 8,675 restricted stock units granted to Wolf on June 5, 2025, fully vested as of November 6, 2025.
Wolf will receive cash compensation at an hourly rate set in accepted statements of work.
2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
SI-BONE announces retirement of President Tony Recupero and appointment of Nikolas Kerr as Chief Commercial Officer.
Tony Recupero, President, Commercial Operations, will retire effective February 15, 2026, and transition to a 12-month advisory role starting February 16, 2026.
Show detailsHide details
Nikolas Kerr, currently Senior Vice President of Product, Marketing and Business Development, will become Chief Commercial Officer effective February 16, 2026.
Recupero's retirement is not due to any disagreement with the company; he will provide consulting services to ensure an orderly transition.
Recupero will receive $12,500 monthly cash compensation during the 12-month consulting term, with continued equity vesting.
The company also reported Q2 2025 revenue of $48.6 million, up 21.7% year-over-year, and raised 2025 revenue guidance to $195-$198 million.
2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits